NAFLD Primary Care

Launched by MAASTRICHT UNIVERSITY · Jun 1, 2021

Keywords

ClinConnect Summary

The NAFLD Primary Care trial is studying non-alcoholic fatty liver disease (NAFLD), which is a common liver condition affecting many people, especially those who are overweight or have diabetes and heart disease. The trial aims to find out how many people in primary care settings have NAFLD and related health issues. By identifying these patients early, healthcare providers can help prevent the disease from getting worse and improve their overall health.

To be eligible for this trial, participants should be between 18 and 80 years old, speak Dutch, and have a body mass index (BMI) over 25, indicating they are overweight. They should also have one of the following conditions: overweight, obesity, type 2 diabetes, or cardiovascular diseases like high blood pressure. Participants will undergo assessments to check for NAFLD and related conditions. It’s important to note that individuals with certain liver diseases, significant alcohol use, or who are pregnant cannot participate. This study will contribute valuable information to better understand NAFLD and help improve care for those affected.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Able to understand and sign the informed consent
• • Able to speak Dutch
• • Between 18-80 years
• • BMI \>25 kg/m²
• • Having one of the following conditions: 1)overweight, 2) obesity, 3) type 2 diabetes mellitus, 4) cardiovascular diseases (hypertension, atherosclerosis, angina pectoris, ischaemic heart condition, cerebrovascular condition)
• Exclusion Criteria:
• • Excessive alcohol use (more than 20 g/day for women and 30g/day for men= \>2 glasses alcohol/day for women and \>3 glasses for men)
• • Other liver diseases: Hepatitis B virus, Hepatitis C virus, autoimmune hepatitis, primary biliary cirrhosis, hemochromatosis, Wilson's disease, Alpha 1 antitrypsin deficiency
• • Secondary causes for steatosis: disorders of lipid metabolism, HCV Genotype 3, total parental nutrition, severe surgical weight loss, medications (amiodarone, tamoxifen, methotrexate, corticosteroids and HAART), lean steatosis, Celiac disease, environmental toxicity
• • Pregnancy and breastfeeding.
• • A history of bariatric surgery.
• • Diagnosis of liver cirrhosis and/or hepatocellular carcinoma.
• • Current diagnosis of extrahepatic malignancy(s) or prior diagnosis within last 5 years.
• • Individuals about to undergo a surgery or otherwise medical procedure that will interfere with data collection and analyses planned within the current cohort, will initially be excluded from participation, but are offered the opportunity to participate at a later moment in time (e.g., after 3 months are myocardial infarction patients are eligible for participation).